Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.

Abstract

The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Brain Neoplasms / classification
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / pathology
  • DNA Mutational Analysis
  • ErbB Receptors / genetics*
  • Factor Analysis, Statistical
  • Gene Dosage
  • Gene Expression
  • Gene Expression Profiling
  • Glioblastoma / classification
  • Glioblastoma / genetics*
  • Glioblastoma / pathology
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Middle Aged
  • Mutation
  • Neurofibromatosis 1 / genetics*
  • Oligonucleotide Array Sequence Analysis
  • Prognosis
  • Receptor, Platelet-Derived Growth Factor alpha / genetics*

Substances

  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • EGFR protein, human
  • ErbB Receptors
  • Receptor, Platelet-Derived Growth Factor alpha

Grants and funding